About this trial

AVMs have been reported to rupture at a formidable annual rate of 2% to 3% at natural progression, often resulting in longterm neurological deficits and poor functional outcomes.The reported risk of hemorrhagic presentation in patients with AVMs is 41% to 65%. While many studies suggest a correlation between higher hemorrhage risk and the concurrent presence of AVM and aneurysms, few authors have focused specifically on flow-related aneurysms alone. In many instances, the source of rupture is also unclear. Meta-analysis from 2016 suggested that 49.2% of hemorrhages were secondary to aneurysm rupture, 45% from AVM rupture, and 5.7% were undetermined.In a study of 302 patients, of which 52.6% had a hemorrhagic presentation, demonstrated a significant increase in rate of hemorrhage in those with flow-related aneurysms. Thus, it is necessary to figure out risk factors related to ruptured flow-related aneurysms in pAVM.

Eligibility criteria

Qualifiers

pAVM with flow-related aneurysms were identified by DSA, and subarachnoid hemorrhage was confirmed by CT

No history of stroke, Marfan syndrome, polycystic kidney disease

Disqualifiers

pAVM without flow-related aneurysms

Absence of clinical data

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

200 Participants
are grouped into 2 trial groups

Locations

2
Jiangsu Province Hospital225500, NanjingJiangsu, China
the First Affiliated Hospital of Nanjing Medical University NanjingJiangsu, China

Sponsors and collaborators

The First Affiliated Hospital with Nanjing Medical University

Lead sponsor